Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.
Medtronic’s investment is contingent on Anteris completing a proposed $200 million public stock offering.
Anteris Technologies says Medtronic will make a strategic investment of up to $90 million in the transcatheter heart valve ...
The Medtronic investment and the underwritten public offering of common stock position Anteris to continue to execute the global PARADIGM Trial and to continue investing in research that can transform ...
GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut ...
Researchers have created a new noninvasive technique for performing a type of artery bypass that may change the future of ...
Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...
On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. In the trial, TAVR, which assists patients suffering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results